Analisis Kadar Serum Glutamic Pyruvic Transminase (SGPT) Pada Penderita Tuberkulosis Paru Rawat Jalan yang Mengkonsumsiobat Anti Tuberkulosis Lebih Dari 3 Bulan

Sari

ABSTRACT

Pulmonary TB (tuberculosis) is an infectious disease caused by the bacterium Mycobacterium tuberculosis which can attack parts of the human body starting from the lungs, joints, intestines, lymph glands, lining of the brain and so on. TB treatment consists of an initial phase and a follow-up phase under direct supervision for 6 months, 9 months or even 12 months to prevent TB infection from developing. This drug is used routinely to prevent resistance to the Mycobacterium tuberculosis germ. Every drug prescribed can cause side effects on other body organs, so the risk of hepatotoxicity is higher than the interactions between the drugs used, including: Isonazid, Rifampicin and Pyrazinamide. Research entitled Analysis of SERUM GLUTAMIC PYRUVIC TRANSMINASE (SGPT) Levels in Outpatient Pulmonary Tuberculosis Patients Who Take Antituberculosis Drugs for More Than 3 Months. The research design used in this research is analytical descriptive with a prediction study approach. The research was conducted at Martha Friska Hospital in Medan, May – August 2023. The results showed that there was an increase in SGPT levels in all outpatient pulmonary TB sufferers who had taken antituberculosis drugs for more than 3 months in the 6-12 year age group of 3 people (15%) , 3 people in the 13-18 year age group (15%) and 14 people in the 19-60 year age group (70%). There were 12 men (60%) and 8 women (40%). The longest duration of antituberculosis treatment was 7 months, namely 5 people (25%) experienced an increase in SGPT levels. The fastest treatment for pulmonary TB sufferers experienced an increase in SGPT levels starting at 4 months, as many as 3 people (15%). Level of Mild Hepatotoxicity was 13 people (65%), Moderate Hepatotoxicity was 6 people (30%), Severe Hepatotoxicity was 1 person (5%)

Keywords: Serum Glutamic Pyruvic Transminase (SGPT) Levels, Pulmonary Tuberculosis Patients

ABSTRAK

TB paru (tuberkulosis) merupakan penyakit menular yang disebabkan oleh kuman Mycobacterium tuberculosis yang bisa menyerang bagian tubuh manusia mulai paru paru, tulang sendi, usus, kelenjar limfe, selaput otak dan sebagainya. Pengobatan TB terdiri atas fase awal dan fase lanjutan dibawah pengawasan langsung selama 6 bulan, 9 bulan bahkan 12 bulan untuk mencegah agar infeksi TB tidak berkembang. Penggunaan obat ini dilakukan secara rutin agar tidak terjadi resistensi terhadap kuman Mycrobacterium tuberculosis. Setiap obat yang diresepkan memungkinkan terjadinya efek samping terhadap organ tubuh lainnya, sehingga resiko hepatotoksik lebih tinggi daripada interaksi obat yang digunakan antara lain: Isonazid, Rifampisin dan Pirazinamid. Penelitian dengan judul Analisis Kadar SERUM GLUTAMIC PYRUVIC TRANSMINASE (SGPT) pada Penderita Tuberkulosis Paru Rawat Jalan Yang Mengkonsumsi Obat Antituberkulosis Lebih dari 3 Bulan. Disain penelitian yang dipakai dalam penelitian ini adalah Deskriptif Analitik dengan pendekatan prediction study. Penelitian dilakukan di RS Martha Friska Medan, bulan Mei – Agustus 2023. Hasil didapatkan  terjadi peningkatan kadar SGPT pada semua penderita TB paru rawat jalan yang telah mengkonsumsi obat antituberkulosis lebih dari 3 bulan dengan kelompok umur 6-12 tahun sebanyak 3 orang (15%), kelompok umur 13-18 tahun sebanyak 3 orang (15%) dan kelompok umur 19-60 tahun sebanyak 14 orang (70%). Jenis kelamin laki-laki sebanyak 12 orang (60%) dan perempuan sebanyak 8 orang (40%). Lama pengobatan antituberkulosis terbanyak jangka waktu 7 bulan yaitu 5 orang (25%) mengalami peningkatan kadar SGPT. Pengobatan penderita TB Paru yang tercepat mengalami peningkatan kadar SGPT dimulai 4 bulan sebanyak 3 orang (15%). Tingkat  Hepatotoksik Ringan sebanyak 13 orang (65%), Hepatotoksik Sedang sebanyak 6 orang (30%), Hepatotoksik Berat Sebanyak 1 orang (5%)

Kata Kunci: Kadar Serum Glutamic Pyruvic Transminase (SGPT), Penderita Tuberkulosis Paru